Research & Development
Breast Cancer: Page 3
FDA clears Angle’s Parsortix breast cancer system
The FDA clearance is the first FDA product clearance to harvest cancer cells from a blood sample for subsequent analysis. This offers the prospect of a new era of personalized cancer care, according to the company.
July 27, 2022
Clinics begin adopting Genetic Technologies risk test
The clinics can focus on testing for a single disease or multiple diseases, including breast cancer, colorectal cancer, ovarian cancer, coronary artery disease, prostate cancer, and type 2 diabetes, the company said.
June 30, 2022
Artemis signs $250M deal for liquid biopsy tests with Datar
The contract gives Artemis DNA the exclusivity to commercialize and distribute the liquid biopsy tests Trucheck Pragma and Cancertrack in the U.S. and Vietnam. Trucheck Pragma is a noninvasive blood-based screening test for lung, stomach, colon, pancreas, prostate, breast, and ovarian cancers; Cancertrack is a cancer monitoring test that allows patients to evaluate response/resistance during treatment and monitor recurrence of cancer.
May 15, 2022
Veracyte touts gene expression study data at ESMO meeting
To generate consensus regarding the clinical utility in breast cancer treatment of GEP tests, including Veracyte's Prosigna breast cancer assay, 133 specialists from 11 European countries were surveyed in the PROCURE study.
May 3, 2022
Agendia highlights presentations at ESMO Breast Cancer 2022
The first poster presentation concluded that the next-generation sequencing versions of MammaPrint and BluePrint are equivalent to a centralized microarray test, according to the vendor.
May 3, 2022
Natera highlights Signatera data at AACR
One study focuses on circulating tumor DNA (ctDNA) prognosis in adjuvant triple-negative breast cancer. Researchers found that 19.9% of patients with early-stage disease were found to have detectable ctDNA after surgery (which was strongly associated with poorer outcomes), and that lead time between first ctDNA positivity and recurrence on imaging was a median of six months.
April 10, 2022
Genetic causes identified for three rare diseases
Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease
SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
Werfen completes $2B acquisition of Immucor, expands presence in specialized diagnostics
Chembio CEO urges stockholders to tender remaining shares as deadline is extended for acquisition
Paige receives marks for breast lymph node AI software
The AI medical device software helps pathologists detect if breast cancer has metastasized to lymph nodes along with review by pathologists.
April 7, 2022
AACR announces 2022 cancer research award recipients
The award recognizes female researchers who have made pioneering contributions to the understanding and treatment of breast and gynecological cancer. This year's awardees include:
April 3, 2022
Ibex launches study of Galen software for breast cancer
The research will review the clinical performance of the AI-based Galen Breast algorithm, which helps pathologists detect and grade different types of invasive and noninvasive breast cancer, in a retrospective study. Also, researchers will evaluate use of the software's second-read application and digital workflow in clinical use at Hartford HealthCare, which has 400 locations serving 185 towns and cities.
March 22, 2022
Paige unveils breast lymph node software at USCAP 2022
Designed to help pathologists detect if breast cancer has metastasized to the lymph nodes, Paige Breast Lymph Node can yield 98% slide-level sensitivity for detecting metastases of any size, according to the vendor. The software's TissueMap tool highlights all regions on a slide that are suspicious for cancer, and both slides and cases with suspected positive lymph nodes are highlighted to facilitate priority review by pathologists, Paige said.
March 21, 2022
Theralink lands payment code for advanced breast cancer assay
Making use of both laser capture microdissection and reverse phase protein array technologies, the Theralink assay measures the tumor cell levels of activated proteins -- the primary targets of most U.S. Food and Drug Administration-approved therapies and biopharmaceutical investigational drugs, according to the company. As a result, oncologists can utilize this potentially predictive molecular tool when selecting appropriate therapies, Theralink said.
March 21, 2022
Mission Bio opens solid tumor research center at MSK
Dr. Reis-Filho, PhD, a breast cancer expert and director of experimental pathology at MSK, will run the center in Manhattan. His lab will drive academic and industrial best practices using single-cell DNA profiling to observe tumor heterogeneity and clonal architecture in solid cancers.
March 1, 2022
Page 3 of 11